Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good luck guys, last one one holds the baby :)
Fun to watch and if the pump gives those trapped at 3p a chance to get out even better
Being positioned with a potential growth story for H2 subject to a discounted placing at a penny. Watch this space.
Just a note to those gamblers buying on pump, just make sure you are not still left in holding the baby when the P &D crew depart.
Got to love AIM
Thanks Porks.
We have cash until December!!
WE WILL GET A DEAL BY XMAS!!!!
VAL 201 OR KINGS!
Valirx has been to 74p before and has been stable for a long time at 20 p and 30 p . I would call that the building phase. We are now at the news stage after the waiting stage.
The RNS highlights all the potential. We know we got cash until H1 2025 but lab revenue is coming as highlighted in the RNS with 12 at late stage negotiations plus large biotechs waiting as clients that will increase confidence. Revenues should increase significantly, 201 deal could well conclude soon taking us past 20p range with a bit of luck.
Upside is very significant and plenty of cash in the bank for now and significant news likely in the coming weeks.
Agreed porky, I feel a little gutted as my small investment here was @3.4p, I sold after the RNS @2.1 so made a loss. But, I am actually still happy with the decision as this has pump and placement written all over it! Gla who are still here, but as porky says be very very careful! I smell I hairy long tailed rat!!
We have plenty of cash well into 2025. If you read the RNS from last week plus revenue to come. No pump but false drop and moving to fairer value which still remains well into double digits. More news will come.
11 clients for the lab plus plus hopefully large deals waiting to be signed on the drug development side.
Expecting 15p minimum by December and that would be just a 20 million market cap. If CLX gets signed then all bets are off.
LMOL
Winner Winner Chicken Dinner, roll up, roll up.
Fools rush in but if it helps those trapped its a good thing.
They haven't found a CEO yet, what next: betting on two snails to see which one beats the other in a race.
Ridiculous
Do I detect a dose of sour grapes porky....Don't think anyones scared enough to listen to you any more... TA TA old bean
Well done to all holders today, long termers or those in for a quick trade 👏 suck it up Porky 🤡
Cash until Feb 2025 PLUS
The number of prospective clients in the sales pipeline for Inaphaea's services and products is continuing to grow, with 11 at an advanced stage of discussion. This includes both screening and licencing of patient derived cells ("PDC"). Interest has been expressed from a range of end users, including biotech companies, large pharma and large CROs
PLUS
Deals for Val 201 and CLX possible.
PLUS a larger market cap with so much news. We could be 20p plus by then. A few evaluations to conclude in the next 6 months as well including and possibly Imperial as like Cathy said that was at a fairly advanced stage.
If they can present like this to an institution It would surprise me if they can get some buyers through the open market.
It should read that it would not surprise me.
How’s the FAB working out for ya Porky Pie…You’re no stranger to placing as FAB had an eye watering 84% discounted placing last year, oh and another placing this year. Enjoy Porker… 😂😂😂
Give up Pigman you just seem desperate and bitter now.
Under offer .Long way to go.
Stick to the facts:
Cash runway now appears sufficient to carry it well into 2025
Full year 2023E Group net losses along with the cost of establishing/facilitating Inaphaea Biolabs (including the
acquisition of Imagen Therapeutics), resulted in an average estimated cash burn of a little over £200,000/month for
the period. If one now prudently assumes further, albeit somewhat reduced, Group net losses for 2024E, during
which time it utilises the newly raised net funding to accelerate exploitation and integration of its acquired BioBank
materials in tandem with commercial development/brand establishment within Inaphaea while also advancing
its preclinical product pipeline in the absence of further cash acquisition(s), the Group now appears to have runway
sufficient to carry it into Q2 2025.
Between now and then, of course, various upside scenarios suggest this period could become significantly extended.
This could be derived through securing higher volumes of fee-paying service customers for Inaphaea, potential
signing of licensing agreements with external parties willing to pay upfront charges and fund ongoing
development of the Group’s preclinical and/or clinical assets which, in turn, could also attract continuing
milestones instalments. Any such outcome could be both transformative for ValiRx’s balance sheet while also
proving its business model.
Not to mention the conclusion of any deals which would massively increase the market cap from these levels given our cash burn is very around 1.5 million after additional cost cutting any future dilution would likely be very minimal. The lab in addition will provide further revenue so high upside with deals on the line and plenty of cash with a low risk strategy given we do not do clinical trials. Low risk, very high reward strategy especially from these levels.
From the RNS:
The number of prospective clients in the sales pipeline for Inaphaea's services and products is continuing to grow, with 11 at an advanced stage of discussion. This includes both screening and licencing of patient derived cells ("PDC"). Interest has been expressed from a range of end users, including biotech companies, large pharma and large CROs. The latter sector is of particular importance as we believe their requirements are substantive and likely to lead to longer term product supply relationships. Although the needs of the individual clients are varied, their decision-making timelines have been impacted by a number of factors, both internal and external, and generally characterised by longer lead times. We maintain regular dialogue with all key clients and, subject to their indicated decision processes and timelines, anticipate that several of the pipeline opportunities could be executed in H2 2024.
Well done all who made money here today! I saw it at 2.6p and decided not to buy as it had already spiked from 1.9p. Great decision by me! lol Can't win them all! Hoping VAL investors have another good day tomorrow!
@porky - 1p Placing at absolute best
A scientist / drug developer said this about the clx news: “Sod it - if CLX001 isn't worth 20M now, I'm giving up the day job and pursuing my life-long dream of becoming a dancer.“
Current market cap is £5m.
No way can you seriously believe that placing will be at 1p after todays new? 😂 😂 😂
This is the person trying to give people advice here after loosing all his money at 4D. Porky take your own advice from one of your own posts and either invest or as you said “FO”
Porky9
Posted in: DDDD.L
Posts: 6,880
Price: 38.85
Strong Buy
RE: Great summary from Sangijuelas from 7th April!!! - thanks Sang
12 Apr 2022 17:19
@Sang
You are interpreting the Oxford Finance situation incorrectly
Read the dam Investment Report issued, they clearly confirm capital into Q4 end of. They also state two further tranches from Oxford of 10m and 7.5m respectfully as required, they have an RnD Tax credit of 9m they have additional filings on the NASDAQ where they could raise a further 150m end of the year if they want. They are in NO hurry.
Further, Duncan confirmed he is in talks with Oxford Finance hence terms could change yet and further we discussed we could see a licence deal land in that time, a payment on the vaccines and other potential additions.
Give it up for Gods sake either invest here or FO. Spreading FUD now is ridiculous. Make better use of your time if you are not invested, why sit here trying to de-ramp whilst something could drop that materially moves the SP north or you just miss a golden opportunity.
The SP is on the floor here at 40 pence not 40 quid. strap a pair on and invest if you are so keen to follow and keep posting.
Ramping here off the scale by select few, how many times have we seen this.
All they have delivered is a balloon in admin costs, nice pay awards and bonuses and nothing else. We still await a replacement CEO. New BOD and new vision.
There is nothing in that RNS except fluff. CLX is the only asset that could one day be something and that is years off. Where's revenue to keep this business coming from? You in the next placing due.
15 + raises and three 125:1 share consolidations and you are calling for more of the same. Jeeze.
All that is happening here is share price pump, select couple of posters with multi alias ramping it to pump it prior to a massive sell off just before discounted placing. The only way cash is landing here is from the next placement. Same old same old. No revenue.
If you are daft enough to buy into this pump just don't be the last one holding the baby. Ridiculous.
Porky, Time to bow out. You have achieved your objective.
@porky - the way the company has been run has been a s hitshow. Have you not read the news about CLX001 yesterday?
A scientist / drug developer said this about the clx news: “Sod it - if CLX001 isn't worth 20M now, I'm giving up the day job and pursuing my life-long dream of becoming a dancer.“
Do you honestly think Adam is ramping?
Actually Adam is ramping.
Who can blame him with his large holding in VAL?
SAR was once worth almost 300 million based on one preclinical deal. I think C4X had a deal for a compound that had less work done than CLX not sure how much it was I think about 15 million upfront payment with a few hundred million in milestone payments.
CLX would probably be worth 20 million plus at this stage if you look at comparables. Late stage preclinical compounds can be worth 100 million plus.
Valirx will want an early deal so no doubt the coming months will be big for CLX. With that we have 201 which can conclude at any point and 401. Lots going on and 11 lab clients including large pharma who could sign up. It can only go up from these levels with cash well into 2025 which will likely increase based on the lab revenue.
Low risk strategy with very high upside. We should keep moving from such a low market cap.